Zimmer Biomet Holdings, Inc.
Zimmer Biomet Holdings, Inc.
Your view on ZBH
Overview
What the company does, where it operates, and who runs it.
About Zimmer Biomet Holdings, Inc.
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Ivan Tornos
- Headquarters
- 345 East Main Street, Warsaw, IN, US
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Ivan Tornos
- Headquarters
- 345 East Main Street, Warsaw, IN, US
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T.
products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.
It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as robotic, surgical and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues.
It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015.
Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Zimmer Biomet Holdings, Inc., and the rating behind it. ZBH last traded at $93.49, 22.6× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Zimmer Biomet Holdings, Inc.. Starting points for Zimmer Biomet Holdings, Inc.: P/E 22.6, EPS $4.20, beta 0.47 — an Medical - Devices name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Zimmer Biomet Holdings, Inc.. Zimmer Biomet Holdings, Inc. paid $0.96 per share over the last year — a 1.0% yield at the current $93.49 price. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Zimmer Biomet Holdings, Inc.. Trailing twelve-month EPS for Zimmer Biomet Holdings, Inc. stands at $4.20. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Zimmer Biomet Holdings, Inc.. Zimmer Biomet Holdings, Inc. has reported as a listed company since 2001. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Zimmer Biomet Holdings, Inc. valued side by side against its closest peers. Zimmer Biomet Holdings, Inc. is measured against Medical - Devices peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Zimmer Biomet Holdings, Inc., and how their positions are changing. At a $18.09B market value, institutional positions materially move Zimmer Biomet Holdings, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Zimmer Biomet Holdings, Inc. executives and directors. Shares of Zimmer Biomet Holdings, Inc. have traded between $85.33 and $114.44 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Zimmer Biomet Holdings, Inc.. Zimmer Biomet Holdings, Inc. is a $18.09B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Zimmer Biomet Holdings, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Zimmer Biomet Holdings, Inc.. Coverage tracks Zimmer Biomet Holdings, Inc. within Medical - Devices (Healthcare). Press releases and market coverage, newest first.